Mycazole (Fluconazole)

Fluconazole, the active ingredient in Mycazole, is an azole antifungal presented as an oral tablet for oral use. It treats systemic and mucosal fungal infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Mycazole as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company emphasizes stringent quality assurance and adherence to international regulatory standards. Mycazole is distributed to a broad network of healthcare institutions, ensuring reliable access to essential antifungal therapy.

Mycazole (fluconazole) is employed to treat fungal infections affecting various organ systems.

- Candidiasis (oral, esophageal, vaginal): reduces fungal load and resolves symptoms in affected sites. - Cryptococcal meningitis: penetrates the central nervous system to treat infection and prevent relapse. - Systemic mycoses: provides systemic coverage against susceptible yeasts and molds in invasive disease. - Dermatophyte infections: treats skin and nail infections caused by dermatophyte fungi. - Oropharyngeal candidiasis: clears infection in the mouth and throat, improving comfort and nutrition.

Fluconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often transient. - Headache: occasional mild to moderate intensity. - Diarrhea: loose stools that usually resolve without treatment. - Rash: mild skin redness or itching. - Abdominal pain: cramp‑like discomfort in the stomach area. - Taste alteration: temporary change in taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: acute allergic response with breathing difficulty and hypotension. - QT prolongation: cardiac rhythm disturbance in susceptible patients.

When prescribing fluconazole, clinicians should consider several safety precautions to minimize risks. - Assess liver function: obtain baseline hepatic enzymes before initiating therapy. - Review concomitant medications: identify drugs that may interact with fluconazole metabolism. - Monitor renal function: adjust dose in patients with severe renal impairment as advised. - Caution in pregnancy: evaluate risk‑benefit ratio, as safety data are limited. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Educate patients on signs of liver injury: advise reporting jaundice, dark urine, or abdominal pain promptly. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Fluconazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause toxic fluconazole levels. - Warfarin: increased anticoagulant effect leading to bleeding risk. - Phenytoin: reduced fluconazole efficacy due to enhanced metabolism.

Moderate Interactions (Monitor Closely): - Oral contraceptives: decreased hormonal efficacy, consider alternative contraception. - Statins (e.g., simvastatin, lovastatin): increased risk of myopathy, monitor muscle symptoms. - Rifampin: may lower fluconazole concentrations, reducing effectiveness. - Antidiabetic sulfonylureas: possible enhanced hypoglycemic effect, monitor glucose.